Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03278665
Other study ID # 4SC-202-2-2017
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 25, 2017
Est. completion date February 2, 2022

Study information

Verified date February 2022
Source 4SC AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab. A dose expansion cohort at the Recommended Phase Two Dose (RPTD) will be added. Adult patients with advanced (unresectable or metastatic) cutaneous melanoma primary refractory or non-responding to anti-PD-1 therapy as most current systemic anti-cancer therapy and for whom no standard therapy is available, will be enrolled. The last administration of anti-PD-1 therapy must have been performed within 6 months prior to screening.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date February 2, 2022
Est. primary completion date February 2, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria: - Patients with unresectable stage III or stage IV cutaneous melanoma, as per American Joint Committee on Cancer (AJCC) (Version 8) staging system (must have been histologically confirmed at least once during course of disease). Patients with metastatic tumor of unknown primary site and histology of melanoma are eligible. - Patients must be primary refractory or non-responding to anti-PD-1 therapy (either as monotherapy or in combination with Ipilimumab) - Measurable disease by computer tomography (CT) or Magnetic resonance imaging (MRI) per immune-related response evaluation criteria in solid tumors (irRECIST) 1.1 criteria, with longest diameter for non-nodal lesions = 10 mm and = 15 mm in short axis for nodal lesions - At least one tumor site (either primary site or metastasis) must be accessible for sequential biopsies and patient must consent to the 2 mandatory biopsies. This requirement is not applicable for continuous dosing schedules and may be waived by the sponsor in other individual cases. Main Exclusion Criteria: - Patients who achieved a CR or PR, during or after prior anti-PD-1 mono- or anti-CTLA-4/anti-PD-1 combination therapy - Patients with symptomatic brain metastases/central nervous system (CNS) involvement - Patients with inadequate organ function - Therapy with agents known to prolong the QT interval and increase the risk for Torsades de Pointes

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
4SC-202 in combination with Pembrolizumab
4SC-202 in combination with Pembrolizumab

Locations

Country Name City State
Germany Universitätsklinikum Essen Essen
Germany Medizinische Hochschule Hannover Hannover
Germany Universitätsklinikum Heidelberg Heidelberg
Germany Klinikum der Universität München München
Germany Universitätsklinikum Tübingen Tübingen
Germany Universitätsklinikum Würzburg Würzburg
Italy Istituto Nazionale Tumori Fondazione "G. Pascale" Napoli

Sponsors (1)

Lead Sponsor Collaborator
4SC AG

Countries where clinical trial is conducted

Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events [Safety and Tolerability] Safety and tolerability of the combination of 4SC-202 and Pembrolizumab will be assessed from adverse events. Up to 114 weeks
Secondary Objective Response Rate (ORR) The Objective Response Rate (ORR) will be defined as the percentage of patients who have achieved a confirmed response of at least Immune-related Complete Response (irCR) or Immune-related Partial Response (irPR) Up to 102 weeks
Secondary Best Overall Response (BOR) The Best Overall Response defined as the best among all confirmed overall responses (irCR is better than irPR is better than irSD) Up to 102 weeks
Secondary Disease Control Rate (DCR) The Disease Control Rate (DCR) will be defined as the percentage of patients who have achieved a confirmed response of at least irCR or irPR or a response of irSD Up to 102 weeks
Secondary Duration of Response (DOR) Duration of response (DOR) is defined as the time from the first documentation of response to the date of disease progression. Patients who have no documented disease progression at the end of the study or who are lost to follow-up or who receive additional anti-neoplastic therapy after discontinuing 4SC-202 and Pembrolizumab will be censored at the date of their last extent of disease assessment or on the first date of additional therapy, respectively. Up to 102 weeks
Secondary Progression Free Survival (PFS) The time from first dosing (C1D1) to date of first observed progression or death from any cause (whichever comes first). Patients who have not progressed while on study and have not died while on study will be censored at the last evaluable assessment date. Up to 102 weeks
Secondary Time to Progression (TTP) The time from first dosing (C1D1) to first date of first observed progression. Patients who have not progressed while on study, have not died while on study or experienced a non-disease- related death will be censored at the last evaluable assessment date. Up to 102 weeks
Secondary Overall Survival (OS) The Overall Survival (OS) is defined as the time from first dosing (C1D1) to date of death from any cause. Patients who have not died while on study will be censored at the last evaluable assessment date Up to 102 weeks
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Completed NCT02935790 - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab Phase 1
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Completed NCT01211262 - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Phase 1
Recruiting NCT03649529 - Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy Early Phase 1
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01455259 - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors Phase 1/Phase 2
Completed NCT00978913 - Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00336986 - Efficacy Study of IL-21 to Treat Metastatic Melanoma Phase 2
Completed NCT00350597 - GM-CSF as Adjuvant Therapy of Melanoma Phase 2
Completed NCT02523313 - Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Completed NCT04253574 - Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
Completed NCT00179608 - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy Phase 1
Terminated NCT00104884 - FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Phase 2
Recruiting NCT04593485 - Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract Phase 2